Ki, or the inhibition constant, is a number that tells you how tightly an inhibitor binds to an enzyme. Specifically, it’s the concentration of inhibitor needed to occupy half of the available enzyme molecules at equilibrium. A lower Ki means the inhibitor binds more tightly and is more potent, while a higher Ki means it binds weakly and takes more of the compound to shut the enzyme down.
If you’re studying biochemistry or trying to understand how drugs work at the molecular level, Ki is one of the most important values you’ll encounter. It’s considered an intrinsic property of the inhibitor itself, meaning it doesn’t change based on how much substrate is present in the experiment. That makes it a more reliable measure of binding strength than some alternatives.
What Ki Actually Measures
Enzymes speed up chemical reactions in your body by binding to molecules called substrates. An inhibitor is any molecule that interferes with this process. When an inhibitor (I) binds to an enzyme (E), it forms an enzyme-inhibitor complex (EI). This binding is reversible, meaning the inhibitor can attach and detach. Ki describes the equilibrium of that reversible process.
Formally, Ki is a dissociation constant. It’s calculated as the concentration of free enzyme multiplied by the concentration of free inhibitor, divided by the concentration of the enzyme-inhibitor complex: Ki = [E][I] / [EI]. When Ki is small, the denominator (the bound complex) is large relative to the numerator (the free components), which means the inhibitor spends most of its time stuck to the enzyme. When Ki is large, the inhibitor mostly floats free and doesn’t bind well.
Think of it like a measure of stickiness. A Ki of 0.1 nanomolar means the inhibitor grabs onto the enzyme extremely tightly at a tiny concentration. A Ki of 100 micromolar means you’d need a much higher concentration of inhibitor to get the same effect. In drug development, researchers routinely compare Ki values to find the most potent compounds. For example, some highly optimized drug candidates achieve Ki values below 1 nanomolar, indicating exceptionally tight binding to their target.
How Ki Changes With Inhibition Type
The way Ki fits into the overall math depends on how the inhibitor interacts with the enzyme. There are three main types of reversible inhibition, and each one changes the enzyme’s behavior differently.
Competitive Inhibition
A competitive inhibitor competes directly with the substrate for the enzyme’s active site. It can only bind the free enzyme, not the enzyme that already has a substrate attached. In this case, the inhibitor effectively makes it harder for the substrate to find an open enzyme, which increases the apparent Km (the substrate concentration needed to reach half-maximum speed) without changing the maximum reaction rate. Ki appears in the velocity equation as a modifier of Km: the apparent Km becomes Km × (1 + [I]/Ki). You can overcome competitive inhibition by flooding the system with substrate.
Non-Competitive Inhibition
A non-competitive inhibitor binds the enzyme at a site other than the active site, and it can latch on whether or not the substrate is already bound. This reduces the maximum reaction rate because some fraction of enzymes are locked in an inactive complex, but the Km stays the same. The velocity equation reflects this: the maximum speed gets divided by (1 + [I]/Ki). Adding more substrate doesn’t help because the inhibitor isn’t competing for the same spot.
Uncompetitive Inhibition
An uncompetitive inhibitor only binds the enzyme-substrate complex, not the free enzyme. This is less common but does occur, particularly in multi-substrate reactions. It reduces both the apparent maximum speed and the apparent Km by the same factor, (1 + [I]/Ki). On a double-reciprocal plot, uncompetitive inhibition produces parallel lines, which is its signature pattern.
In mixed inhibition, which sits between competitive and non-competitive, researchers often define two separate constants: one for binding the free enzyme and another for binding the enzyme-substrate complex. The ratio between these two constants determines where the inhibition pattern falls on the spectrum.
Ki vs. IC50
IC50 and Ki both describe how effective an inhibitor is, but they measure different things. IC50 is the inhibitor concentration that cuts enzyme activity in half under a specific set of experimental conditions. Ki is the true binding affinity between the inhibitor and the enzyme.
The critical difference: IC50 values shift depending on how much substrate is present, what substrate you use, and other assay conditions. Ki values are, in principle, independent of those variables. Two labs running the same inhibitor under different substrate concentrations will get different IC50 values but should get the same Ki.
You can convert between the two using the Cheng-Prusoff equation: Ki = IC50 / (1 + [S]/Km), where [S] is the substrate concentration used in the experiment and Km is the enzyme’s Michaelis constant. This equation applies specifically to competitive inhibitors and assumes a simple one-substrate reaction. When the substrate concentration is much lower than Km, IC50 and Ki converge to roughly the same number. When the substrate concentration is high, IC50 can be substantially larger than Ki because more inhibitor is needed to outcompete the abundant substrate.
Because IC50 depends on experimental conditions, combining IC50 data from different laboratories or different assays introduces significant noise. Ki values are more comparable across studies, which is why they’re preferred for head-to-head comparisons of inhibitor potency.
How Scientists Measure Ki
Determining Ki experimentally requires running enzyme activity assays at multiple inhibitor concentrations and multiple substrate concentrations. The classic approach uses graphical methods. In a Dixon plot, you plot 1/velocity on the y-axis against inhibitor concentration on the x-axis, with separate lines for each substrate concentration. For competitive inhibition, the lines intersect above the x-axis, and the x-coordinate of that intersection point gives you negative Ki.
Double-reciprocal plots (also called Lineweaver-Burk plots) are another standard tool. You plot 1/velocity against 1/substrate concentration, drawing separate lines for each inhibitor concentration. The pattern of those lines tells you the inhibition type: lines converging on the y-axis indicate competitive inhibition, lines converging to the left of the y-axis suggest mixed inhibition, lines intersecting on the x-axis point to pure non-competitive inhibition, and parallel lines signal uncompetitive inhibition. Once you know the type, you can extract Ki from the relationships between the slopes or intercepts.
Modern labs typically fit their data to kinetic equations using nonlinear regression software rather than relying on graphical methods alone. This gives more precise Ki estimates and avoids the distortions that can occur when transforming data for linear plots.
Why Ki Matters in Drug Development
Most drugs that target enzymes or receptors are inhibitors of some kind, and Ki is one of the primary numbers used to evaluate them. During lead optimization, medicinal chemists systematically modify a molecule’s structure and measure how each change affects Ki. The goal is to push Ki as low as possible for the intended target while keeping it high for related proteins, achieving both potency and selectivity.
Real-world Ki values span an enormous range. Morphine, for instance, binds the mu-opioid receptor with a Ki of about 1.8 nanomolar. Some highly optimized drug candidates reach Ki values in the picomolar range (thousandths of a nanomolar), like certain migraine-related compounds that achieve Ki values of 0.035 nanomolar against their target while showing selectivity ratios of over 4,000-fold against related receptors.
Ki also helps researchers understand selectivity. If a compound has a Ki of 1 nanomolar for its target but a Ki of 12,000 nanomolar for a closely related protein, you can be confident it will preferentially hit the intended target at therapeutic doses. This selectivity ratio is a core part of deciding which compounds move forward into clinical trials.
Factors That Can Shift Ki Values
Although Ki is treated as a fixed property of an inhibitor-enzyme pair, environmental conditions can change it. Temperature is one important variable. Binding interactions involve energy exchanges, so raising or lowering the temperature shifts the equilibrium between bound and unbound states. pH matters too, because both the enzyme and inhibitor may contain groups that gain or lose protons at different pH levels, altering the shape and charge of the binding site. Ionic strength, the type and concentration of salts in solution, can also influence binding.
This is why published Ki values always come with experimental conditions attached. A Ki measured at 25°C and pH 7.4 may not match one measured at 37°C and pH 6.5. When comparing Ki values across studies, checking that the conditions are reasonably similar is important for drawing valid conclusions.